![]() |
It would be interesting to know who makes up the sample group of 1100.
|
Most of the rest of the world is ahead of us in this. We learned about chloroquine and HQC from the Chinese and the French.
Both drugs are old, and fairly easy to make, having very established ‘recipes’. For $20k in hardware and $40k in starting reagents, I could make 10kg in my basement at 90% yield. Then all you need is a pill press. It’s not hard... So what I cannot fathom, is that given these things, IF it is the ‘magic bullet’, wouldn't COVID19 be a non issue...cause those countries ahead of us would already be using it to the fullest? Are we the only ‘smart ones’ on the planet? The cynic in my says the current studies are just a cash grab. |
Quote:
Meawhile, the French and Chinese studies got published: https://www.medrxiv.org/content/10.1101/2020.03.16.20037135v1 https://www.ncbi.nlm.nih.gov/pubmed/32164085 |
That’s not true. Mylen got a very plump contract to make HQC. Workers are Half time, but getting full time pay.
Emergency contacts are lucrative. |
Fuzzy results around Chlorquine, but there's a promising drug being used in new trials: leronlimab
|
Quote:
https://www.fiercepharma.com/pharma/new-commitments-mylan-and-teva-move-to-supply-tens-millions-hydroxychloroquine-tablets-to I also think zinc has a key role to play in prevention. |
Quote:
|
I’m sure we will find out up the road. Somebody will FOIA it at some point.
Mostly Past experience. I’ve been on both sides, government and performer. Typical fee built in is 8-10%. That’s big company. Stop every you are doing and do this now from my past experience is typically 40% fee. I may be wrong and Mylen is being altruistic... |
|
Quote:
http://forums.pelicanparts.com/uploa...1586103211.png |
Notice mylen isn’t on that list...
|
Quote:
G&A? Profit? Other Allowable Costs? In any event, it seems the production of the drug is not an issue and will be supplied without government contracts in the near term. Good. |
There is a fee written into any government contract I’ve ever submitted. I worked at BAE for 8 years and it was 10%. Direct profit for doing the work. It’s own line item. That was on any contract, be it DARPA, DHS, NRL, or DTRA.
|
Drug is cheap and easy to make. A 100L reactor would easily make 20-40kg.
Any big company capable would be stupid not to. Cheapest advert you could get once this is over. But I’m a cynic. |
Quote:
Impressive speed. Quote:
|
India has banned the export of their domestic supplies of HCQ. Interesting that they feel compelled to hang onto it.
https://theprint.in/india/governance/india-bans-export-of-hydroxychloroquine-as-coronavirus-cases-jump-to-over-3000/395766/ |
Last report I saw was that NY was scheduled to start testing HQC on the 24th of march.
Does anybody know if that actually happened? We are two weeks from that date. Both the French and Chinese papers said that significant improvements were noted within 5 days. I haven't heard anything about if HQC has made any difference. Any links anyone? BTW, they are using a lot of it. The Wuhan paper says the patients got 400 mg/day for 5 days. The French paper was 600 mg/day for 6 days. Malaria treatment is 300 mg/week. HQC does cause serious lengthening of QT, so may not be suitable for someone already crashing. |
|
Quote:
:( |
"President Trump’s former lawyer Michael Cohen has explained why Novartis paid him $1.2m to act as a consultant on the Trump administration, to the embarrassment of the drugmaker.
Cohen’s testimony in front of a congressional committee yesterday was notable for departing from Novartis’ version of events in a number of respects, including how many times he had contact with the pharma giant, and what Novartis hoped to achieve through the relationship. He told the House Oversight committee members that Novartis’ $1.2m fee was intended to get him to work as lobbyist who could provide access to President Trump and other government officials, while Novartis has previously suggested it was intended for general information on the administration’s approach to healthcare policy. Cohen also said he had interacted with Novartis on half a dozen occasions, whereas the company’s original account insisted they had direct contact only once, and he claimed Novartis sought him out, rather than vice versa. Pressed by lawmakers, Cohen said that Novartis wanted him to help unravel “the enigma of Donald Trump,” adding that he “crossed out” a clause in a contract sent over by the drugmaker that asked him to work as a lobbyist, according to Reuters. Last year, Novartis rejected claims it misled the Senate over its links to Cohen, and disputed suggestions former CEO Joe Jimenez had multiple discussions with the lawyer. Nevertheless, the case led to the resignation of legal head Felix Ehrat (pictured below), who accepted responsibility for making the payments." |
All times are GMT -8. The time now is 10:56 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Search Engine Optimization by vBSEO 3.6.0
Copyright 2025 Pelican Parts, LLC - Posts may be archived for display on the Pelican Parts Website